Vacek V
Klinika infekcních nemocí 3, LF UK, Praha.
Cas Lek Cesk. 1993 Jan 26;132(1):24-8.
The author presents a review if pharmacokinetics, undesirable effects, drug interactions, dosage, indications and drug forms of antiviral chemotherapeutic agents used for systemic treatment: amantadine and rimantadine (influenza virus A), acyclovir (HSV-1, HSV-2 and VZV), ganciclovir (CMV), zidovudine (HIV), ribavirine (broad spectrum) and fosfocarnet (herpes viruses and HIV), mentioning also vidarabine. All mentioned preparations are at least in some countries commercially available. The author does not mention virostatic agents used only locally and preparations which are at present in the stage of clinical tests.
作者对用于全身治疗的抗病毒化疗药物的药代动力学、不良反应、药物相互作用、剂量、适应症和剂型进行了综述：金刚烷胺和金刚乙胺（甲型流感病毒）、阿昔洛韦（单纯疱疹病毒1型、单纯疱疹病毒2型和水痘带状疱疹病毒）、更昔洛韦（巨细胞病毒）、齐多夫定（人类免疫缺陷病毒）、利巴韦林（广谱）和膦甲酸钠（疱疹病毒和人类免疫缺陷病毒），还提到了阿糖腺苷。所有提及的制剂至少在一些国家有商业销售。作者未提及仅局部使用的病毒抑制剂和目前处于临床试验阶段的制剂。
